Less than 7% of the US population has optimal cardiometabolic health according to a novel study that assessed 5 key components of the measure. That disappointing metric and others like it have fueled a surge in research into cardiometabolic disease pathophysiology, prevention, and treatment.
Click through the 12 slides in this update for an at-a-glance overview of 2022's most promising cardiometabolic research to date.
CKD, Heart Failure, Hypertension, MACE, NAFLD/NASH, Type 2 Diabetes
US Cardiometabolic Health in Steady Decline, Racial/Ethnic Minorities at High Risk